Cutting Edge: Low-dose Recombinant IL-2 Treatment Prevents Autoantibody Responses in Systemic Lupus Erythematosus via Regulatory T Cell–independent Depletion of T Follicular Helper Cells
The Journal of Immunology · 15.10.2024 · 213 (8) · 1053-1060
DOI: 10.4049/jimmunol.2400264 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.08.2024. Verfasst von Silvia Santana und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Interleukin-2, T-Lymphocytes, Regulatory, Autoantibodies. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI), NIAID NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
The expansion of T follicular helper (Tfh) cells correlates with disease progression in human and murine systemic lupus erythematosus (SLE). Unfortunately, there are no therapies to deplete Tfh cells. Importantly, low-dose rIL-2–based immunotherapy shows potent immunosuppressive effects in SLE patients and lupus-prone mice, primarily attributed to the expansion of regulatory T cells (Tregs). However, IL-2 can also inhibit Tfh cell differentiation. In this study, we investigate the potential of low-dose rIL-2 to deplete Tfh cells and prevent autoantibody responses in SLE. Our data demonstrate that low-dose rIL-2 efficiently depletes autoreactive Tfh cells and prevents autoantibody responses in lupus-prone mice. Importantly, this immunosuppressive effect was independent of the presence of Tregs. The therapeutic potential of eliminating Tfh cells was confirmed by selectively deleting Tfh cells in lupus-prone mice. Our findings demonstrate the critical role of Tfh cells in promoting autoantibody responses and unveil, (to our knowledge), a novel Treg-independent immunosuppressive function of IL-2 in SLE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
- Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL.
- Section of Cardio-Renal Physiology and Medicine, Division of Nephrology, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL.
ORCID-Profile: Jeremy B Foote, Holly Bachus, Beatriz León, Carmen De Miguel, André Ballesteros-Tato
Förderung
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- NIAID NIH HHS
- NIDDK NIH HHS
- NHLBI NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
Zitieren
APA
Santana, S., Papillion, A., Foote, J. B., Bachus, H., León, B., De Miguel, C., & Ballesteros-Tato, A. (2024). Cutting Edge: Low-dose Recombinant IL-2 Treatment Prevents Autoantibody Responses in Systemic Lupus Erythematosus via Regulatory T Cell–independent Depletion of T Follicular Helper Cells. The Journal of Immunology, 213(8), 1053-1060. https://doi.org/10.4049/jimmunol.2400264
Vancouver
Santana S, Papillion A, Foote JB, Bachus H, León B, De Miguel C, et al. Cutting Edge: Low-dose Recombinant IL-2 Treatment Prevents Autoantibody Responses in Systemic Lupus Erythematosus via Regulatory T Cell–independent Depletion of T Follicular Helper Cells. The Journal of Immunology. 2024;213(8):1053-1060. doi:10.4049/jimmunol.2400264
BibTeX
@article{Santana2024,
author = {Santana, Silvia and Papillion, Amber and Foote, Jeremy B and Bachus, Holly and León, Beatriz and De Miguel, Carmen and Ballesteros-Tato, André},
title = {Cutting Edge: Low-dose Recombinant IL-2 Treatment Prevents Autoantibody Responses in Systemic Lupus Erythematosus via Regulatory T Cell–independent Depletion of T Follicular Helper Cells},
journal = {The Journal of Immunology},
year = {2024},
volume = {213},
number = {8},
pages = {1053--1060},
doi = {10.4049/jimmunol.2400264}
}
EUVIMED